Abbott Laboratories (ABT) Q3 FY26 earnings call

Abbott announced its intention to spin off its Nutrition business into an independent, publicly traded company, aiming to unlock value by allowing both entities to sharpen strategic focus and investment. The company delivered accelerated top and bottom-line growth in the third quarter, driven by strong performance in Medical Devices and EPD, despite some near-term challenges in specific segments. Management remains confident in its robust pipeline and ability to drive sustainable growth and margin expansion for the remaining Abbott portfolio.